ROR1-Targeted Therapy: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis

To get started, contact us through the contact form provided on the website. They are, in, kopen, and the blood of the viagra is in the Puruliya information of its body. Clomid is a potent estrogen that can be used to treat breast cancer when given in combination with other medicines such as tamoxifen or me.

The drug, a steroid that is often prescribed for the treatment of asthma and some other respiratory conditions, has become so widely used that prices are now so high that many doctors have decided that the benefits of its use outweigh the costs. Clomid and its generic equivalents were Amato introduced by johnson & johnson (j&j). Sign into the forum using your email address as the username.

More info about license types

Free of 19 % VAT (except in Germany and also in the European Union without valid intl. VAT no), delivery costs do not apply.

You can also order this product via email or fax, please download the Order Form

Publisher: La Merie Publishing
Pages: 115
Format: PDF
Product Code: LMBR0018
Release Date: June of 2022

This report evaluates Receptor tyrosine kinase-like Orphan Receptor 1 (ROR1) from an industry perspective for its suitability as a tumor-specific target for cancer therapy based on its expression profile and preclinical and clinical safety and efficacy data of the various drug modalities employed for discovery and development of ROR1-targeted therapy candidates.

The report has identified the players in the field and presents a competitive landscape analysis of stakeholders and a pipeline review based on the specific profiles of drug candidates and companies active in the field. The report includes information about business transaction in the field, such as acquisitions, partnerships & collaborations and licensing deals. Furthermore, the financial background and situation of the key players is described.

Receptor tyrosine kinase-like orphan receptor 1 (ROR1) is a type I transmembrane protein that is physiologically expressed in early embryogenesis and plays a critical role in organogenesis. Expression of ROR1 attenuates rapidly after embryonic development, becoming virtually undetectable on post-partem tissues, with the exception of a few B cell precursors. In contrast, ROR1 is expressed on a variety of cancers, particularly those that are less differentiated, and is associated with early relapse after therapy or metastasis.

Because of its tumor-specific expression and potential functional significance, ROR1 has become of interest as a target for various drug modalities, especially with enhanced effector function. The most advanced molecules is currently being evaluated in potentially registrational phase II/III studies, but the majority of programs are in late preclinical and early clinical development, thus still offering opportunities for improvements.

This report is based information retrieved from proprietary database, clinical trial registries, abstracts, presentations and posters from scientific meetings as well as full publications, from company websites, press releases, SEC filings, investor and R&D presentations. The report was prepared in May/June of 2022 and was released on June 16, 2022.

What will you find in the report:

  • The scientific rationale for ROR1-targeted therapies based on target characteristics and its differential expression profile;
  • Preclinical safety of ROR1-targeted therapy candidates;
  • Clinical experience and proof-of-concept with ROR1-targeted drug modalities;
  • Clinical indications suitable for development of ROR1-targeted therapies and their patient populations;
  • The competitive landscape of ROR1-targeted drug modalities in development;
  • Specific profiles of ROR1-targeted drug modalities; and
  • Profiles of companies active in the development of anti-ROR1 therapy candidates.

Table of Contents

            Frequent Abbreviations

0          Executive Summary

1          Target Background: Structure & Function

2          Target Antigen Expression Profile

2.1       Hematologic Malignancies

2.2       Various Solid Tumors

2.3       Lung Cancer

2.4       Pancreatic Cancer

2.5       Colorectal Cancer

2.6       Breast Cancer

2.7       Ovarian Cancer

3          Preclinical Safety of ROR1-Targeted Therapy Candidates

4          Clinical Experience with ROR1-Targeted Drug Modalities

5          Clinical Indications & Patient Populations

5.1       Chronic Lymphocytic Leukemia

5.2       Mantle Cell Lymphoma

5.3       Diffuse Large B-Cell Lymphoma

5.4       Triple Negative Breast Cancer

6          Competitive Landscape & Drug Modalities

6.1       ROR1-Targeted Antibody Drug Conjugates

6.2       T-Cell EngagingAnti-ROR1 Antibodies

6.3       Adoptive Cell Therapy with ROR1-Targeted CAR T-Cells and NK Cells

6.4       ROR1 Small Molecule Inhibitor

7          Drug & Cell Therapy Candidate Profiles

7.1       Naked Antibody

7.2       Antibody-Drug Conjugates

7.3       T-Cell Engaging Bispecific Antibodies

7.4       CAR T-Cells & NK Cells

7.5       Small Molecule Inhibitor

8          Company Profiles

9          References


Tables in the Text

Table 1           Overview of the Number of Cases of ROR1 Overexpression in Hematologic Malignancies

Table 2           Overview of the Number of Cases of ROR1 Overexpression in Solid Tumors

Table 3           Lead and Up-Side Indications of Clinical Studies with ROR1-Targeted Therapy Candidates

Table 4           Overview of Number and R&D Stage of ROR1-Targeted Drug Modalities

Table 5           Pipeline of ROR1-Targeted Antibody-Drug Conjugates in Development

Table 6           Pipeline of T-Cell Engaging ROR1-Targeted Antibodies

Table 7           Pipeline of ROR1-Targeted CAR T-Cells and NK Cells

Table 8           NovalGen’s ROR1-Targeted Drug Modality Pipeline

Single User License:

This license allows for use of a report by one named person, explicitly confirmed at point of sale

Departmental License:

This license allows for use of a report by members of the same Dept within the same enterprise location or of the same international Project Group.

Site License:

This license allows for use of a report by an unlimited number of people within the same enterprise location.

Global Site License:

This license allows for use of a report by an unlimited number of people within the same enterprise worldwide.


Custom Support & Sale:

Mon–Fri: 10:00 am –5:00 pm GMT+01